Lectins; A Hope of Treatment For COVID-19 |Biomedgrid

COVID-19, a newly emerged infectious disease caused by SARS-CoV-2, arose in Wuhan China. Which is a challenge for scientists worldwide. The available vaccine is expensive and not easily assessable. However, the most of the enveloped viruses' express glycoproteins on their surface. While lectins are proteins that directly bind to glycosylated residues, and certain lectins have been suggested as viral infection therapies. Many antiviral lectins have been successfully used against hepatitis C, influenza A/B, herpes, Japanese encephalitis, HIV and Ebola. Lectin have shown significant activity against SARS coronavirus that occurred in 2003. This agent is cheap and easily accessible, if it succeeds in SARS-CoV-2 treatment, it will have a huge advantage. In order to treat COVID-19, scientific attention is needed on lectins.